

1/30




FIG. 1A




FIG. 1B

2/30




FIG.2

3/30




FIG.3

4/30





FIG.4

5/30

Human EphA2 Expression in CT26 Subclones
Generation of "the Super Clone"



• Subclones of transfected clones obtained by FACS sorting into 96 well plates

FIG.5

6/30




FIG.6

7/30

Human EphA2 Protein Expression in B16F10 Cells
Round 3




FIG. 7

8/30




FIG.8

9/30




FIG. 9A



FIG. 9B

10/30





FIG.10A

11/30



* p=0.0017

FIG.10B

12/30




FIG.11A

Effect of *L. monocytogenes* Expressing ECD of huEphA2 on
CT26 huEphA2 Tumor Growth
Prevention Study






FIG.11B



15/30



16/30




FIG. 12

17/30

Effect of *L. monocytogenes* Expressing ECD
of huEphA2 on CT26 Tumor Growth
Therapeutic Study




FIG. 13A

Effect of *L. monocytogenes* Expressing ECD
of huEphA2 CT26 Tumor Growth
Therapeutic Study




FIG.13B

19/30




FIG. 13C

20/30




FIG. 14A

21/30





FIG.14B

22/30



Days Post IV Injection of 2e5 CT26.24 (huEphA2+) Cells

FIG.14C

23/30




FIG. 14D

24/30




FIG. 14E

25/30




FIG.14F

26/30




FIG.15

27/30




FIG. 16

28/30




FIG.17

29/30




FIG.18A

30/30




FIG. 18B